Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function

Clinical Therapeutics

Volumn 39, Issue 1, 2017, Pages 159-169

  Rondinelli, Maurizio ^a   Rossi, Antonio ^a   Gandolfi, Alessandra ^a,b   Saponaro, Fabio ^c   Bucciarelli, Loredana ^a   Adda, Guido ^a   Molinari, Chiara ^a,b   Montefusco, Laura ^a   Specchia, Claudia ^a,d   Chiara Rossi, Maria ^e   Scardapane, Marco ^e   Arosio, Maura ^a,c   Genovese, Stefano ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Center for Outcomes Research and Clinical Epidemiology   (Italy)

Author keywords

effectiveness; liraglutide; real world; type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; METFORMIN; SHORT ACTING INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LIPID;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG EFFICACY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; KIDNEY FUNCTION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ITALY; METABOLISM; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ITALY; LIPIDS; LIRAGLUTIDE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85008196941     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.11.001     Document Type: Article

References (27)

1. 1 Madsbad, S., Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18 (2016), 317–332.
2. 2 Bode, B., An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 97 (2012), 27–42.
3. 3 Lapolla, A., Frison, V., Bettio, M., et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther 37 (2015), 574–584.
4. 4 Buysschaert, M., D׳Hooge, D., Preumont, V., Roots Study Group. ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. Diabetes Metab Syndr 9 (2015), 139–142.
5. 5 Ponzani, P., Long-term effectiveness and safety of liraglutide in clinical practice. Minerva Endocrinol 38 (2013), 103–112.
6. 6 Mezquita-Raya, P., Reyes-Garcia, R., Moreno-Perez, O., et al. Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Ther 6 (2015), 173–185.
7. 7 Sun, F., Wu, S., Guo, S., et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 110 (2015), 26–37.
8. 8 Sun, F., Wu, S., Wang, J., et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther 37 (2015), 225–241 e8.
9. 9 Sun, F., Wu, S., Guo, S., et al. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine 48 (2015), 794–803.
10. 10 Zavattaro, M., Caputo, M., Samà, M.T., et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50 (2015), 620–626.
11. 11 Buysman, E.K., Liu, F., Hammer, M., Langer, J., Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther 32 (2015), 341–355.
12. 12 Ostawal, A., Mocevic, E., Kragh, N., Xu, W., Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther 7 (2016), 411–438.
13. 13 Li, C.J., Yu, Q., Yu, P., et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol, 13, 2014, 36.
14. 14 Davies, M.J., Bain, S.C., Atkin, S.L., et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care 39 (2016), 222–230.
15. 15 von Scholten, B.J., Lajer, M., Goetze, J.P., et al. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 32 (2015), 343–352.
16. 16 Morano, S., Romagnoli, E., Filardi, T., et al. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol 52 (2015), 727–732.
17. 17 Russo, G.T., Labate, A.M., Giandalia, A., et al. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest 38 (2015), 81–89.
18. 18 von Scholten, B.J., Ørsted, D.D., Svendsen, A.L., et al. The influence of pharmaceutically induced weight changes on estimates of renal function: a patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. J Diabetes Complications 29 (2015), 1146–1151.
19. 19 von Scholten, B.J., Hansen, T.W., Goetze, J.P., et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 29 (2015), 670–674.
20. 20 Griffioen, K.J., Wan, R., Okun, E., et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 89 (2011), 72–78.
21. 21 Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
22. 22 Klonoff, D.C., Buse, J.B., Nielsen, L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24 (2008), 275–286.
23. 23 Lind, M., Hirsch, I.B., Tuomilehto, J., et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, 351, 2015, h5364.
24. 24 Ahmann, A., Rodbard, H.W., Rosenstock, J., NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 17 (2015), 1056–1064.
25. 25 de Wit, H.M., Vervoort, G.M., Jansen, H.J., et al. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes׳ (ELEGANT) randomized controlled trial. J Intern Med 279 (2016), 283–292.
26. 26 Ingelfinger, J.R., Rosen, C.J., Cardiac and Renovascular Complications in Type 2 Diabetes–Is There Hope?. N Engl J Med 375 (2016), 380–382.
27. 27 Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.